Roivant Sciences Ltd.
ROIV
$11.31
-$0.05-0.44%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -206.48M | 169.38M | -- | 95.30M | -151.12M |
| Total Depreciation and Amortization | 8.16M | 1.94M | -- | 4.88M | 13.79M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -8.74M | -325.47M | -- | -212.01M | 12.91M |
| Change in Net Operating Assets | 34.48M | -53.11M | -- | -81.00M | 15.96M |
| Cash from Operations | -172.57M | -207.25M | -- | -192.83M | -108.46M |
| Capital Expenditure | -811.00K | -1.83M | -- | -965.00K | -349.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | 74.93M | 154.44M | -- | -- | -804.00K |
| Other Investing Activities | 1.00B | 301.46M | -- | -- | 8.08M |
| Cash from Investing | 1.07B | 454.07M | -- | -965.00K | 6.93M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.00 | -49.09M | -- | -1.83M | -7.67M |
| Issuance of Common Stock | 12.97M | 28.12M | -- | 2.27M | 3.66M |
| Repurchase of Common Stock | -302.91M | -251.98M | -- | -661.06M | -28.61M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 112.78M | -- | -- | -- | 0.00 |
| Cash from Financing | -177.15M | -272.95M | -- | -660.62M | -32.62M |
| Foreign Exchange rate Adjustments | -489.00K | -1.07M | -- | -2.74M | -855.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 723.99M | -27.20M | -- | -857.15M | -135.01M |